Abstract:Tetanus toxin (TeNT) and botulinum neurotoxins (BoNTs) are neuroprotein toxins, with the latter being the most toxic known protein. They are structurally similar and contain three functional domains: an N-terminal catalytic domain (light chain), an internal heavy-chain translocation domain (HN domain), and a C-terminal heavy chain receptor binding domain (Hc domain or RBD). In this study, fusion functional domain molecules consisting of the TeNT RBD (THc) and the BoNT/A RBD (AHc) (i.e., THc-Linker-AHc and AHc-Linker-THc) were designed, prepared, and identified. The interaction of each Hc domain and the ganglioside receptor (GT1b) or the receptor synaptic vesicle glycoprotein 2 (SV2) was explored in vitro. Their immune response characteristics and protective efficacy were investigated in animal models. The recombinant THc-linker-AHc and AHc-linker-THc proteins with the binding activity had the correct size and structure, thus representing novel subunit vaccines. THc-linker-AHc and AHc-linker-THc induced high levels of specific neutralizing antibodies, and showed strong immune protective efficacy against both toxins. The high antibody titers against the two novel fusion domain molecules and against individual THc and AHc suggested that the THc and AHc domains, as antigens in the fusion functional domain molecules, do not interact with each other and retain their full key epitopes responsible for inducing neutralizing antibodies. Thus, the recombinant THc-linker-AHc and AHc-linker-THc molecules are strong and effective bivalent biotoxin vaccines, protecting against two biotoxins simultaneously. Our experimental design will be valuable to develop recombinant double-RBD fusion molecules as potent bivalent subunit vaccines against bio-toxins.Key points• Double-RBD fusion molecules from two toxins had the correct structure and activity.• THc-linker-AHc and AHc-linker-THc efficiently protected against both biotoxins.• Such bivalent biotoxin vaccines based on the RBD are a valuable experimental design.

Recombinant L-HN Fusion Antigen Derived from the L and HN Domains of Botulinum Neurotoxin B Stimulates a Protective Antibody Response Against Active Neurotoxin

Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F

Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

The Receptor Binding Domain of Botulinum Neurotoxin Serotype A (BoNT/A) Inhibits BoNT/A and BoNT/E Intoxications In Vivo

Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E

Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate

Evaluation of a Recombinant Hc of Clostridium botulinum Neurotoxin Serotype F as an Effective Subunit Vaccine

Biology Activity and Characterization of the Functional L-HN Fragment Derivative of Botulinum Neurotoxin Serotype E.

Expression,Purification and Specific Monoclonal Antibody Preparation of Protective Hc Gene of Botulinum Neurotoxin Serotype A

Production and Evaluation of a Recombinant Subunit Vaccine Against Botulinum Neurotoxin Serotype B Using a 293E Expression System.

Tetanus toxin and botulinum neurotoxin–derived fusion molecules are effective bivalent vaccines

High-Level and Soluble Expressions of Botulinum Neurotoxin Serotype B Protective Antigen Hc Domain in Escherichia coli

The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate

A New Neutralizing Antibody Against Botulinum Neurotoxin B Recognizes the Protein Receptor Binding Sites for Synaptotagmins II.

Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E

Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E

Development and Evaluation of Candidate Vaccine and Antitoxin Against Botulinum Neurotoxin Serotype F

Generation of A Recombinant Full-Length Human Antibody Binding to Botulinum Neurotoxin A

Neutralizing Antibodies Of Botulinum Neurotoxin Serotype A Screened From A Fully Synthetic Human Antibody Phage Display Library

High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E